Rexahn Pharmaceuticals Announces Publication of Study on Neuroprotective Effects of Clavulanic Acid Sep 21, 2010
Rexahn Pharmaceuticals Announces the Appointment of Peter Brandt and Richard Kivel to Board of Directors Sep 13, 2010
Rexahn Pharmaceuticals to Present at the Rodman & Renshaw 12th Annual Healthcare Conference Sep 8, 2010
Rexahn Pharmaceuticals Submits Serdaxin Phase IIb Protocol to FDA for Major Depressive Disorder (MDD) Sep 7, 2010
Rexahn Pharmaceuticals Announces Publication of New Preclinical Research Data for Novel Anticancer Compound RX-8243 Sep 2, 2010
Rexahn Pharmaceuticals Announces Formation of Scientific Advisory Board in Major Depressive Disorder Jul 6, 2010